Liposomal NAD+ is one of the more expensive and heavily promoted forms available on the NAD+ supplement market. Products in this category are offered by Quicksilver Scientific, Cymbiotika, RHO, Renue by Science, Goldman Laboratories and other brands, among others.
The main marketing argument is better absorption.
The premise is that encapsulating NAD+ in a lipid carrier can protect the molecule as it passes through the digestive tract and potentially improve its delivery compared to standard oral NAD+.
From the point of view of formulation technology, this is a rational concept.
However, the most important question is whether the liposomal delivery method actually provides a significant advantage in humans, or is merely a more technologically advanced formulation concept.
In this article, we explain why unmodified oral NAD+ encounters absorption problems, what the purpose of liposomal encapsulation is, how liposomal NAD+ compares to standard capsules and sublingual products, what laboratory research currently shows, and what human study data is still lacking.
Why does oral NAD+ have a problem with absorption?
Unmodified NAD+ is not ideally suited for straightforward absorption when taken orally, as it is a relatively large, highly charged, and water-soluble molecule.
These properties create several barriers that the molecule must overcome before reaching the systemic circulation.
The molecular mass of NAD+ is approximately 663 Daltons. [1]
Its size and strong negative charge hinder passive transport across the intestinal epithelium compared with many smaller and less polar compounds.
The bowel wall acts as a selective barrier.
Smaller substances with properties more compatible with cell membranes typically penetrate through them more easily than large and strongly charged molecules, such as NAD+.
There is also a second problem.
The digestive tract and liver contain enzymes that actively break down NAD+ and related molecules as part of normal nucleotide and coenzyme metabolism.
This means that an orally administered NAD+ molecule must overcome both physical barriers to absorption and enzymatic degradation.
Even smaller NAD+ precursors, such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), undergo significant metabolic transformation during digestion and first-pass hepatic metabolism before reaching the systemic circulation. [1,2]
Unmodified NAD+ enters the same metabolic environment, whilst having a larger molecular structure and properties that are less favourable for passive absorption.
This connection helps to explain why most clinical trials on NAD+ supplementation focus on precursors rather than unaltered oral NAD+.
NR and NMN are smaller molecules which, once absorbed, can enter the body's NAD+ biosynthesis pathways.
Liposomal NAD+ uses a different strategy.
Instead of changing the administered molecule, liposomal formulations are intended to improve the delivery of unchanged NAD+ by protecting it as it passes through the digestive tract.
What does liposomal delivery actually mean?
A liposome is a microscopic structure formed from a lipid bilayer.
It can be thought of as a small vesicle made up of lipids, which encloses an internal space.
Water-soluble substances, such as NAD+, can theoretically be trapped within this space.
This kind of delivery technology has a real pharmaceutical application.
Liposomal formulations are used in some approved medicines, including certain anticancer drugs, where encapsulation can alter drug distribution, protect the active substance or limit specific adverse effects.
The proposed benefit for NAD+ is based on the same general principle.
The lipid layer is designed to protect the NAD+ molecule from adverse conditions in the digestive tract.
In theory, this can limit degradation caused by the stomach environment and digestive enzymes before the molecule has time to be absorbed.
Another potential benefit is the effect on cellular uptake.
Cell membranes are also largely composed of lipid bilayers.
Because liposomes have a similar membrane structure, they can interact with cells differently than free, water-soluble NAD+.
Theoretically, liposomes can fuse with cell membranes or be taken up via other transport mechanisms, potentially delivering their contents more effectively.
This makes the concept of liposomal NAD+ scientifically credible.
It also differs from attempts to passively transport unchanged NAD+ through the skin using a simple transdermal patch.
However, a biologically plausible delivery mechanism is not the same as a confirmed clinical advantage.
Whether liposomal NAD+ actually works better must be demonstrated in pharmacokinetic and clinical studies in humans.
Liposomal NAD+ vs standard capsules and sublingual NAD+
These three formats use different strategies designed to influence NAD+ availability.
| Feature | Standard oral capsule | Tablet or sublingual lozenge | liposomal formulation |
|---|---|---|---|
| What does it usually contain | NAD+ precursor, such as NR, NMN, niacin or nicotinamide; sometimes unchanged NAD+ | NAD+ precursor or, less commonly, unchanged NAD+ | NAD+ or precursor enclosed in a lipid bilayer |
| Assumed route of absorption | Standard absorption in the gastrointestinal tract | Assumed partial absorption through the oral mucosa | Gastrointestinal delivery with lipid encapsulation designed to protect the active substance |
| Mechanistic rationale for unchanged NAD+ | Weaker due to size and charge of NAD+; better documented for NR and NMN | Theoretically possible, but the specific uptake of NAD+ is poorly characterised | Credible, because lipid encapsulation can protect a large, charged and water-soluble molecule [1] |
| Randomised human trials | More potent for NR and NMN, with numerous placebo-controlled trials [3,4] | No dedicated comparative studies on NAD+ absorption have been identified | There is a lack of sufficient peer-reviewed clinical data confirming the bioavailability or superiority of liposomal NAD+ |
| Supporting laboratory tests | Comprehensive resources for biology: NR and NMN | Limited | Cell culture studies support the biological rationale for the liposomal formulation [5] |
| Relative cost | Usually the lowest | Moderate | Usually the highest among oral forms |
The table shows an important distinction.
Standard capsules have the strongest evidence base, but this relates primarily to NR and NMN rather than unmodified NAD+.
Liposomal products aim to address a different problem: the effective delivery of unchanged NAD+.
Do studies show that liposomal NAD+ works better?
There is currently not enough peer-reviewed clinical evidence to state that liposomal NAD+ works better than standard oral NAD+, NR, or NMN.
The theoretical justification for using liposomes is credible.
Lipid encapsulation can protect a water-soluble substance, affect its stability, and alter the way it interacts with cell membranes.
However, the likely mechanism does not automatically confirm greater bioavailability in humans.
Demonstrating such an advantage would require pharmacokinetic studies measuring NAD+ and its metabolites in blood, cells or tissues following comparable doses of different formulations.
Randomised clinical trials would also have to assess not only biomarkers, but also meaningful functional outcomes.
Based on current evidence, it cannot be confirmed that liposomal NAD+ improves energy levels, physical performance, cognitive function, metabolism, biomarkers associated with biological ageing, or other health indicators.
What do the laboratory tests show?
Further information is provided by studies on cell cultures.
One study compared liposomal and non-liposomal NAD+ in cultured human endothelial cells and keratinocytes. [5]
The liposomal formulation produced stronger effects in relation to certain cellular markers associated with cellular ageing.
This supports the concept that lipid encapsulation can alter how NAD+ interacts with cells.
However, this was an in vitro study.
Cell culture does not reproduce the full biological process that occurs after a human swallows the product.
Digestion, intestinal absorption, hepatic metabolism, circulation, tissue distribution and cellular uptake create additional barriers that are not present in the cell culture experiment.
The laboratory results therefore support the biological plausibility of this concept.
However, they do not prove that the same effects occur in a living human organism.
What evidence is still missing?
The most important missing evidence is a completed, peer-reviewed, human head-to-head comparative study.
Among the studies identified, no publication was found that directly compared equivalent doses:
- liposomal NAD+;
- standard non-liposomal NAD+;
- oral NMN;
- oral NR.
Without such a study, it is difficult to determine which delivery method produces the greatest increase in NAD+ in the blood, cells or tissues per milligram administered.
It is also unknown which form provides the most lasting effect.
Most importantly, there is a lack of strong evidence showing that liposomal NAD+ provides better functional health outcomes than standard NAD+ precursors.
The current application must therefore remain limited.
Liposomal NAD+ has a biologically plausible rationale and support in cell culture research, but its bioavailability, clinical efficacy and superiority over better-studied oral NR or NMN have not been established.
Which brands offer liposomal NAD+?
Several brands sell products described as liposomal NAD+.
These include Quicksilver Scientific, Cymbiotika, RHO, Renue by Science, Goldman Laboratories and other manufacturers.
Products may be available in the form of liquids, capsules, drops, sachets or single portions.
However, the presence of the term „liposomal” does not mean that all these products are equivalent.
The quality of liposomal formulations can vary significantly.
Key variables include:
- lipid composition;
- particle size;
- production technique;
- encapsulation performance;
- product stability;
- percentage of the declared NAD+ actually encapsulated in liposomes.
These factors can affect the behaviour of a specific formulation.
Results for a specific laboratory formulation should not automatically be applied to every commercial product labelled as liposomal NAD+.
Individual products may differ in lipid composition, particle size, stability, encapsulation efficiency and actual NAD+ content.
A similar problem applies more broadly to NR and NMN supplements.
Clinical trials often use a specific compound or formulation of research grade.
Consumer products may contain the same general ingredient, but they do not have to be manufactured or characterised in an identical manner.
What is worth checking when comparing products?
One of the useful parameters is whether the manufacturer provides actual data regarding the liposomal particle size.
The mere inclusion of the word „liposomal” on the label does not confirm the presence of a stable and well-characterised liposomal system.
Another important parameter is the encapsulation efficiency.
It indicates what proportion of the active NAD+ is actually inside the liposomes and how much remains free in the surrounding fluid.
Independent analytical research may also be useful.
A Certificate of Analysis, or CoA, can help confirm whether the amount of NAD+ in a product matches the value stated on the label.
The exact active substance must also be verified.
Some products widely promoted as liposomal NAD+ may in fact contain an NAD+ precursor, such as NMN, instead of unmodified NAD+.
This distinction matters because the evidence base for unmodified NAD+, NMN, and NR is not the same.
The transparency of production is also important.
Information on raw material sourcing, quality control procedures, stability testing, and manufacturing in compliance with Good Manufacturing Practice standards can help distinguish a well-characterised formulation from a product that relies mainly on marketing terminology.
Does liposomal NAD+ justify the higher price?
Liposomal NAD+ is usually more expensive than standard oral NR or NMN.
The higher price is partly due to the additional production stages needed to create and stabilise the lipid delivery system.
However, it is not known whether this price difference is scientifically justified.
Why might a higher cost be justified?
The delivery concept is chemically logical.
Unmodified NAD+ is a large, charged, water-soluble molecule and undergoes metabolic conversion in the digestive tract.
Encapsulating it within lipid structures is a sensible way of mitigating some of these problems.
Cell culture studies also suggest that under experimental conditions, liposomal NAD+ can induce stronger cellular effects than NAD+ without the liposomal formulation. [5]
These results support the biological plausibility of the formulation, but do not confirm its bioavailability or clinical benefit in humans.
Why should a higher price be approached with caution?
Direct human trials concerning liposomal NAD+ remain very limited.
There is a lack of adequately designed, peer-reviewed clinical studies confirming that this formulation provides significant benefits in terms of biomarkers, wellbeing, or functional health outcomes.
There is also no completed, peer-reviewed comparative study showing that liposomal NAD+ increases NAD+ levels more effectively than NR or NMN.
Such a comparison is important because NR and NMN already have a significantly larger base of randomised human trials. [3,4]
The lack of direct comparative data also means it is not possible to reliably calculate whether liposomal NAD+ provides a greater increase in NAD+ relative to the money spent.
The quality of commercial formulations can also vary.
Two products do not have to work in the same way just because both are sold as liposomal.
The conclusion based on the current evidence is relatively straightforward.
If the priority is choosing an oral NAD+-related product with the largest and most mature human research base, NR and NMN are currently better documented.
If the interest is specifically in delivering unchanged NAD+ via a potentially protective lipid system, liposomal NAD+ represents a biologically plausible, but still experimental, concept.
It should not be described as a method with confirmed bioavailability, clinical efficacy, or superiority over standard NAD+ precursors.
Liposomal NAD+: The evidence in brief
| Research question | Current evidence |
|---|---|
| Does unaltered oral NAD+ face absorption issues? | Yes, because of their molecular weight, charge and metabolism [1,2] |
| Can liposomes protect water-soluble compounds? | Yes, as a general principle governing the formulation and administration of medicines |
| Is liposomal NAD+ a biologically plausible concept? | Yes |
| Has an increase in intracellular NAD+ been confirmed in humans? | There is insufficient peer-reviewed research to support this conclusion |
| Has liposomal NAD+ been shown to improve energy or wellbeing? | Not |
| Are there supportive studies on cell cultures? | Yes [5] |
| Has liposomal NAD+ been directly compared with NR or NMN in a matched human trial? | Not set |
| Has a clinical advantage over standard capsules been demonstrated? | Not |
| Are all commercial liposomal NAD+ products equivalent? | There is no evidence to support this assumption |
| Has the cost-effectiveness of a higher price been scientifically proven? | Not set |
Frequently asked questions about liposomal NAD+
What is liposomal NAD+?
Liposomal NAD+ is NAD+ enclosed in microscopic lipid structures called liposomes.
The purpose of such a formulation is to protect the molecule during its passage through the digestive tract and potentially improve its absorption or delivery to cells.
Why is NAD+ put into liposomes?
Unmodified NAD+ is relatively large, highly charged and soluble in water.
These properties hinder simple passive intestinal absorption.
Liposomal encapsulation is designed to protect the molecule and potentially improve its delivery.
Is liposomal NAD+ better absorbed?
This has not been confirmed in properly designed, peer-reviewed comparative studies involving humans.
Lipid encapsulation could, in theory, protect NAD+ and influence its delivery. However, there is a lack of head-to-head studies confirming greater bioavailability than that of standard NAD+, NR or NMN.
Is liposomal NAD+ better than NMN?
This has not been demonstrated.
NMN has a larger body of randomised human trials assessing NAD+-related biomarkers. [3]
Liposomal NAD+ has mechanistic and laboratory evidence to support it, but its clinical advantage over NMN has not been confirmed.
Is liposomal NAD+ better than NR?
There is insufficient evidence to confirm such an advantage.
NR has been evaluated in numerous placebo-controlled randomised trials, whereas direct clinical data regarding liposomal NAD+ remain significantly more limited. [4]
Does liposomal NAD+ increase energy?
This has not been demonstrated in reliable clinical trials.
A probable biological mechanism or an effect observed in cultured cells does not automatically confirm increased energy, improved performance or a sense of well-being in humans.
Are all brands of liposomal NAD+ the same?
No.
The composition of liposomes, particle size, encapsulation efficiency, stability, the quality of ingredients and manufacturing processes may vary between brands.
Results for one specific formulation cannot be automatically applied to every commercial product.
What should you look out for when choosing a product containing liposomal NAD+?
Useful information may include:
- the exact active substance;
- the declared NAD+ content;
- independent laboratory testing;
- certificate of analysis;
- liposomal particle size data;
- encapsulation performance;
- stability data;
- transparent production standards.
The word „liposomal” in itself provides very little information about the actual quality of the formulation.
Limitations of current evidence
The most important limitation is the lack of a sufficient number of peer-reviewed clinical studies evaluating liposomal NAD+ specifically.
The current rationale is based mainly on the chemical properties of NAD+, general principles of liposomal formulation and laboratory experiments.
The second limitation is the lack of direct comparisons.
Among the cited publications, there is no completed, peer-reviewed human study directly comparing liposomal NAD+ with NR, NMN, or standard non-liposomal NAD+ at matched doses and the same pharmacokinetic endpoints.
This precludes drawing definitive conclusions regarding relative bioavailability.
Supporting mechanistic evidence also includes in vitro studies. [5]
Cell culture results can support the biological plausibility of the mechanism, but they do not reproduce digestion, hepatic metabolism, systemic circulation, tissue distribution, or full human physiology.
Another limitation is the differences between commercial products.
Results for a specific laboratory formulation should not be automatically generalised to products from Quicksilver Scientific, Cymbiotika, RHO, Renue by Science, Goldman Laboratories or other brands, unless that exact product has been independently tested.
The quality of the formulation may also vary.
Liposome size, lipid composition, encapsulation efficiency, product stability and actual NAD+ content are not always disclosed by manufacturers to the same extent.
The cost-effectiveness of this delivery method has also not been established.
Without appropriately matched human studies, there is no strong evidence showing that the higher price of liposomal NAD+ translates into proportionally greater bioavailability or better clinical outcomes than cheaper oral NR or NMN.
Current evidence therefore allows liposomal NAD+ to be described as a biologically plausible delivery method supported by laboratory data, but not as a confirmed alternative superior to more established oral NAD+ precursors.
Disclaimer
The article is for educational and scientific-information purposes only. It does not constitute medical advice, therapeutic guidelines, dosage instructions, product recommendations, or an endorsement of liposomal NAD+, standard NAD+, NR, NMN, or any of the commercial brands mentioned.
Liposomal NAD+ has a plausible mechanistic rationale as a delivery method, yet there is a lack of sufficient peer-reviewed clinical evidence confirming its bioavailability or benefits in humans. Laboratory results should not be interpreted as proof of better absorption, improved clinical outcomes, anti-ageing effects, or greater efficacy compared to standard NAD+ precursors.
NAD+ and its associated products are not approved by the FDA or EMA for the treatment, prevention, or cure of diseases. Brand names are provided solely to describe products available on the market. Their mention does not imply independent clinical validation, recommendation, or equivalence to any specific liposomal formulation used in scientific research.
References
[1] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[2] Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
[3] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomised, multicentre, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[4] Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. https://doi.org/10.1038/s41467-018-03421-7
[5] Ministrini, S., Liberale, L., Erle, H.-E., Percoco, G., Tfayli, A., Assi, A., Kapitonov, I., Greiner, I., & Camici, G. G. (2025). A liposomal formulation enhances the anti-senescence properties of nicotinamide adenine-dinucleotide (NAD+) in endothelial cells and keratinocytes. Current Issues in Molecular Biology, 47(9), 722. https://doi.org/10.3390/cimb47090722